绝经前激素受体阳性乳腺癌内分泌治疗现状

doi:10.11904/j.issn.1002-3070.2017.02.015

摘要/Abstract

摘要： 内分泌治疗是激素受体阳性乳腺癌患者术后辅助治疗的重要手段之一。在内分泌治疗的背景下,接受5年他莫昔芬治疗一直是绝经前患者的标准治疗方案。近年来,这一标准受到挑战。许多大型随机临床试验结果为绝经前患者辅助内分泌治疗提出了新的选择。本文拟将绝经前激素受体阳性乳腺癌患者的内分泌治疗现状做一综述。

关键词: 乳腺癌, 绝经前, 内分泌治疗

Abstract: Endocrine therapy is one of the important treatments of adjuvant therapy among patients with positive hormone receptor breast cancer.In the endocrine therapy setting,5 years of tamoxifen therapy has been the standard treatment regimen for premenopausal patients.In recent years,this standard has been challenged.The results of many large randomized clinical trials have made a new choice for adjuvant endocrine therapy in premenopausal patients.In this paper,we review the present situation of endocrine therapy in premenopausal patients with positive hormone receptor breast cancer.

Key words: Breast cancer, Premenopausal, Endocrine therapy

中图分类号:

R246.5

石磊(综述), 许培权(审校). 绝经前激素受体阳性乳腺癌内分泌治疗现状[J]. 实用肿瘤学杂志, 2017, 31(2): 170-174.

SHI Lei,XU Peiquan. The present situation of endocrine therapy in premenopausal patients with positive hormone receptor breast cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 170-174.

参考文献

1 Lei F,Kathrin S,Jun J,et al.Breast cancer in China[J].Lancet Oncol,2014,15(7):279-289.
2 Siegel R,Naishadham D,Jemal A.Cancer statistics 2013[J].CA Cancer J Clin,2013,63(1):11-30.
3 荆长军,魏海霞.复发转移性乳腺癌的内分泌治疗策略[J].临床合理用药,2013,6(8):177-178.
4 Ye S,Sae J,Yeon S,et al.MiRNAs involved in LY6K and estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer[J].Oncotarget,2016,7(27):42261-42262.
5 Kathrin S,Tanja B,Lei F,et al.Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer[J].The Breast,2013,22(3):171-175.
6 Yu K,Wu J,Shen Z,et al.Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis:implication for extended endocrine therapy[J].Clin Endocrinol Metab,2012,97(12):2201-2209.
7 He M,Tang L,Yu K,et al.Treatment outcomes and unfavorable prognostic factors in patients with occult breast cancer[J].Eur J Surg Oncol,2012,38(11):1022-1028.
8 Montemurro F,Del M,De L,et al.Endocrine therapy in premenopausal women with breast cancer:a critical appraisal of current evidence[J].Expert Review of Anticancer Therapy,2016,16(2):211-218.
9 Davies C,Pan H,Godwin J,et al.Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer:ATLAS,a randomised trial[J].Lancet,2013,381(9869):805-816.
10 Gray R,Rea D,Handley K,et al.ATTom:long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer[J].Clin Oncol,2013,31(18):2631-2632.
11 Li J,Shao Z.Endocrine therapy as adjuvant or neoadjuvant therapy for breast cancer:selecting the best agents,the timing and duration of treatment[J].Chin Clin Oncol,2016,5(3):1-12.
12 中国乳腺癌内分泌治疗专家共识专家组.中国乳腺癌内分泌治疗专家共识(2015年版)[J].中国癌症杂志,2015,25(9):755-759.
13 Gu R,Jia W,Zeng Y,et al.A comparison of survival outcomes and side effects of toremifene or tamoxifen therapy in premenopausal estrogen and progesterone receptor positive breast cancer patients:a retrospective cohort study[J].BMC Cancer,2012,12(1):1-10.
14 Souhami L,Bae K,Pilepich M,et al.Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy:a secondary analysis of RTOG 85-31[J].J Clin Oncol,2009,27(13):2137-2143.
15 Aleksander C,Serena W,Deborah T.Optimal management of the premenopausal patient with estrogen receptor-positive breast cancer[J].ASCO Educationcal Book,2014,34(1):12-15.
16 Goldhirsch A,Wood W,Coates A,et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736-1747.
17 Tevaarwerk A,Wang M,Zhao F,et al.Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative,hormone receptor-positive breast cancer(E-3193,INT-0142):a trial of the Eastern Cooperative Oncology Group[J].Clin Oncol,2014,32(35):3948-3958.
18 Francis P,Regan M,Fleming G,et al.Adjuvant ovarian suppression in premenopausal breast cancer[J].N Engl J Med,2015,372(5):436-446.
19 Mathew A,Davidson N.Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer[J].Breast,2015,24(2):120-125.
20 Marco C,Elisabetta M.Picking the optimal endocrine adjuvant treatment for pre-menopausal women[J].Breast,2015,24(2):11-14.
21 Lorenzo R,Olivia P.The Modern landscape of endocrine therapy for premenopausal women with breast cancer[J].Breast Care,2015,10(5):312-315.
22 Burstein H,Lacchetti C,Anderson H,et al.Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer:American society of clinical oncology clinical practice guideline update on ovarian suppression[J].Clin Oncol,2016,34(10):1689-1701.
23 Saranya C.Clinical utilities of aromatase inhibitors in breast cancer[J].Int J Womens Health,2014,7(2):493-499.
24 杨梅.他莫昔芬与来曲唑在绝经后乳腺癌辅助内分泌治疗中临床对比研究[J].海南医学院学报,2016,22(9):910-912.
25 Bernhard J,Luo W,Ribi K,et al.Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression(TEXT and SOFT):a combined analysis of two phase 3 randomised trials.[J].Lancet Oncol,2015,16(7):848-858.
26 Cossetti R,Tyldesley S,Speers C,et al.Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008[J].Clin Oncol,2015,33(1):65-73.
27 Pagani O,Regan M,Walley B,et al.Adjuvant exemestane with ovarian suppression in premenopausal breast cancer[J].N Engl J Med,2014,371(2):107-118.
28 Ribeiro J,Cardoso MJ.Highlights from the Tenth European Breast Cancer Conference(EBCC10),Amsterdam,9-11 March 2016[J].Ecancer medical science,2016,10:644.
29 李卉,张翠英,王珏,等.乳腺癌的内分泌治疗研究进展[J].内蒙古医学杂志,2012,44(1):64-68.
30 Meng Z,Ramaswamy B.Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer[J].World J Clin Oncol,2014,5(3):248-262.
31 Oesterreich S,Davidson NE.The search for ESR1 mutations in breast cancer[J].Nat Genet,2013,45(12):1415-1416.
32 廖宁.启示与创新-展望2015年乳腺癌辅助内分泌治疗[J].循证医学,2015,15(3):134-137.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[3]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[4]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[5]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[6]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[7]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[8]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[9]	林荣杰, 尹航, 周云峰. ON123300对ER阳性人乳腺癌MCF-7细胞的影响及机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 193-197.
[10]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[11]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[12]	殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.
[13]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.
[14]	陈琢, 孔艺然. 沉默UHRF1对乳腺癌细胞增殖和转移的影响[J]. 实用肿瘤学杂志, 2017, 31(6): 512-518.
[15]	李红阳, 孙亮, 姜醒, 苑光军, 刘艳. 蝙蝠葛碱在人乳腺癌MCF-7细胞对5氟尿嘧啶敏感性的研究[J]. 实用肿瘤学杂志, 2017, 31(5): 385-389.